NCT06444880: An ongoing trial by M.D. Anderson Cancer Center
This trial is ongoing. It must report results 3 years, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06444880 |
|---|---|
| Title | Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 9, 2024 |
| Completion date | July 31, 2028 |
| Required reporting date | July 31, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 3, 2025 |
| Days late | None |